Tirzepatide for women with early-stage endometrial cancer and obesity
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman over 18 years old.
- You have been diagnosed with endometrial intraepithelial neoplasia (precancerous changes) or grade 1 endometrial cancer (a low-grade cancer in the lining of the uterus).
- You are scheduled to have a hysterectomy (surgery to remove the uterus) as part of your standard care.
- Your body mass index (BMI) is over 30, which is considered obese.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have not taken any weight-loss medications in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
This study tests a weight-loss medication (tirzepatide) combined with a hormonal intrauterine device (IUD) to treat early-stage endometrial cancer or precancerous changes. The goal is to see if this approach can make the condition go away and possibly avoid more invasive surgery.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.